You are here

Article info

Article menu
Download PDFPDF
Poster exhibition Day 2
P172 Preclinical evidences of the therapeutic potential of ABTL0812 in endometrial cancer

Authors

  • A Gil-Moreno Gynecological Oncology Department, CIBERONC., Hospital Universitari Vall d’Hebron, Barcelona PubMed articlesGoogle scholar articles
  • I Felip Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida PubMed articlesGoogle scholar articles
  • CP Moiola Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Barcelona PubMed articlesGoogle scholar articles
  • C Megino-Luque Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Lleida PubMed articlesGoogle scholar articles
  • C Lopez-Gil Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Universitat Autònoma de Barcelona PubMed articlesGoogle scholar articles
  • S Cabrera Gynecological Oncology Department, Vall Hebron University Hospital, CIBERONC, Vall Hebron University Hospital PubMed articlesGoogle scholar articles
  • S Solé-Sánchez Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona PubMed articlesGoogle scholar articles
  • P Muñoz-Guardiola Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona PubMed articlesGoogle scholar articles
  • E Megias-Roda Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona PubMed articlesGoogle scholar articles
  • H Pérez-Montoyo Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona PubMed articlesGoogle scholar articles
  • J Alfon Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona PubMed articlesGoogle scholar articles
  • MY-V Yeste-Velasco Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona PubMed articlesGoogle scholar articles
  • M Santacana Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida PubMed articlesGoogle scholar articles
  • X Dolcet Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida PubMed articlesGoogle scholar articles
  • A Reques Pathology Department, Vall Hebron University Hospital, Vall Hebron University Hospital PubMed articlesGoogle scholar articles
  • A Oaknin Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital PubMed articlesGoogle scholar articles
  • V Rodríguez-Freixinos Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital PubMed articlesGoogle scholar articles
  • JML Lizcano Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona PubMed articlesGoogle scholar articles
  • C Domènech Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona PubMed articlesGoogle scholar articles
  • X Matias-Guiu Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida PubMed articlesGoogle scholar articles
  • E Colas Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Lleida, Spain PubMed articlesGoogle scholar articles
  • N Eritja Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida PubMed articlesGoogle scholar articles

Citation

Gil-Moreno A, Felip I, Moiola C, et al
P172 Preclinical evidences of the therapeutic potential of ABTL0812 in endometrial cancer
International Journal of Gynecologic Cancer 2019;29:A162-A163.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.